Luciano Prossomariti

Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging

A. Pepe, Antonella Meloni, Marcello Capra et al. · Haematologica · 2010 · 145 citations · Full text

Medicine, Cardiology, Pharmacotherapy +17

Evaluation of the efficacy of oral deferiprone in <i>β</i>‐thalassemia major by multislice multiecho T2*

Alessia Pepe, Massimo Lombardi, Vincenzo Positano et al. · European Journal Of Haematology · 2006 · 125 citations

Medicine, Cardiology, Radiology +17

Costs, quality of life, treatment satisfaction and compliance in patients with β-thalassemia major undergoing iron chelation therapy: the ITHACA study

L Scalone, LG Mantovani, Marieke Krol et al. · Current Medical Research and Opinion · 2008 · 111 citations

Pharmacy, Hematology, Pharmacoeconomics +17

Improving survival with deferiprone treatment in patients with thalassemia major: A prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies

Aurelio Maggio, Angela Vitrano, Marcello Capra et al. · Blood Cells Molecules and Diseases · 2009 · 96 citations

Medicine, Hematology, Pharmacology +6

Long‐term sequential deferiprone–deferoxamine <i>versus</i> deferiprone alone for thalassaemia major patients: a randomized clinical trial

Aurelio Maggio, Angela Vitrano, Marcello Capra et al. · British Journal of Haematology · 2009 · 70 citations

Medicine, Pharmacology, Pharmacotherapy +14